**August 13, 2026**

| | |
|---|---|
| National Stock Exchange of India Limited<br>Exchange Plaza, C-1, Block G,<br>Bandra Kurla Complex,<br>subBandra (East)<br>Mumbai – 400 051<br>**Scrip Symbol: GALAXYSURF** | BSE Limited,<br>Listing Department,<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street,<br>Mumbai- 400001<br>**Scrip Code: 540935** |

**Sub: Investor presentation on the Unaudited Financial Results for the quarter ended June 30, 2026.**

**Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/ Madam,

We are enclosing Investor Presentation on the Unaudited Financial Results for the quarter ended June 30, 2026.

The information is also hosted in announcement section on the website of the Company at www.galaxysurfactants.com.

We request you to take the same on record.

Yours faithfully,
**For Galaxy Surfactants Limited**

Niranjan Arun Ketkar Digitally signed by Niranjan Arun Ketkar Date: 2026.08.13 23:08:50 +05'30'

**Niranjan Ketkar**
Company Secretary
encl: as above

# Galaxy Surfactants Limited

**Result Presentation**
**August'26**

Chemistry
Creates Care

# Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Galaxy Surfactants Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This Presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

# Company at a Glance

**215+ Product Grades**

Performance Surfactants: 47+
Specialty Care Products: 168+

**Extensive R&D Capabilities**

100+ Members
R&D Centre
Pilot Plant
Product Application Centre

**7 Strategically Located Facilities with Inhouse Project Execution Capabilities**

5 in India
1 in Egypt
1 in US

**Serving 1,500+ Clients**

**Presence across 95+ countries**

**2,000+ Employees across all our Facilities**

As on 30th June 2026

# Q1FY27
# Performance Highlights

 

# Management Commentary

**Mr. K. Natarajan**
**Managing Director**

*"I am pleased that the strategic foundations we have been building over the years have translated into tangible outcomes. Our ability to anticipate risks, manage volatility, make disciplined commercial decisions and leverage a diversified portfolio has enabled us to emerge stronger despite a challenging external environment.*

*This performance is also a reflection of the exceptional efforts and collaboration demonstrated by our teams across business development, commercial excellence, procurement, global logistics, manufacturing and operations, who have ensured agility, continuity and flawless execution amidst significant external disruptions.*

*While we remain watchful of evolving geopolitical developments and their impact on global supply chains, we are encouraged by the recovery in customer demand, the strong momentum in Specialty Care and the continued strength of our India business.*

*We remain confident in our ability to deliver sustainable long-term growth through disciplined execution, customer centric approach and a continued focus on creating long-term value for all stakeholders."*

# Key Developments

GALAXY
Chemistry Creates Care

**Consolidated volume growth** in the **mid-single digits**, with a balanced contribution from both Performance Surfactants and Specialty Care

Strong earnings recovery, with **EBITDA growing 87% YoY to ₹252 Cr and EBITDA/MT improving to ₹35,458/MT**, driven by disciplined pricing, a favourable product mix within the Specialty Care segment, operational excellence, improved operating leverage and robust risk management, despite a volatile raw material environment

**India returned to double-digit volume growth after nearly two years**, significantly outpacing market growth, driven by strong demand from Tier-1 customers and the return of reformulation-related volumes that had been impacted in earlier quarters

**AMET** witnessed a low-single-digit YoY decline due to geopolitical disruptions in West Asia. Encouragingly, the **region recorded high-teen sequential growth**, indicating a steady improvement in market conditions and a recovery in demand

**ROW delivered mid-single-digit growth**, led by APAC and improving momentum in the Americas following the revision of US tariffs

**Raw material markets remained volatile**, with elevated fatty alcohol prices and higher petrochemical feedstock costs following the increase in crude oil prices

# Segment Performance Highlights: Q1FY27

GALAXY
Chemistry Creates Care

| Performance Surfactants Revenue | | Specialty Care Revenue | | Total Revenue |
|---|---|---|---|---|
| ₹ 1,178.7 cr | + | ₹ 603.2 cr | = | ₹ 1,781.9 cr |

| Volume Summary | |
|---|---|
| **Category** | |
| **Performance Surfactant** | Mid Single Digit Growth |
| **Specialty Care** | Mid Single Digit Growth |
| **Regions** | |
| **India** | Low Double Digit Growth |
| **AMET** | Low Single Digit Decline |
| **ROW** | Mid Single Digit Growth |

**Overall Mid Single Digit Volume Growth on YoY**

# Consolidated Performance: Q1FY27

Rs in cr

## Total Revenue




## EBITDA




## PAT



# Revenue Performance: Q1FY27

GALAXY
Chemistry Creates Care

## Category




## Customer




## Region wise Revenue



# Consolidated Profit & Loss Statement

| Particulars (Rs. In Crores) | Q1FY27 | Q1FY26 | Y-o-Y | Q4FY26 | Q-o-Q | FY26 |
|---|---|---|---|---|---|---|
| Net Revenue from Operations | **1,781.9** | **1,277.9** | **39.4%** | **1,314.7** | **35.5%** | **5,248.3** |
| Other Income | 3.3 | 11.2 | | 0.3 | | 22.1 |
| **Total Revenue** | **1,785.2** | **1,289.2** | **38.5%** | **1,315.0** | **35.8%** | **5,270.4** |
| Cost of Material Consumed | 1,260.3 | 942.8 | | 975.1 | | 3,917.7 |
| Employee's Benefits Expense | 100.1 | 83.5 | | 83.9 | | 328.1 |
| Other Expenses | 172.2 | 127.8 | | 134.0 | | 527.3 |
| **EBITDA** | **252.5** | **135.1** | **86.9%** | **121.9** | **107.1%** | **497.4** |
| **EBITDA Margin** | **14.1%** | **10.5%** | | **9.3%** | | **9.4%** |
| Depreciation | 36.0 | 29.3 | | 33.2 | | 123.0 |
| **EBIT** | **216.5** | **105.8** | **104.7%** | **88.7** | **144.2%** | **374.4** |
| Finance cost | 9.3 | 6.6 | | 8.5 | | 30.9 |
| **PBT (Before Exceptional)** | **207.2** | **99.2** | **108.9%** | **80.2** | **158.4%** | **343.5** |
| Exceptional Item | 0.0 | 0.0 | | 0.0 | | 11.9# |
| **PBT (AfterExceptional)** | **207.2** | **99.2** | **108.9%** | **80.2** | **158.4%** | **331.6** |
| Tax expense | 41.3 | 19.7 | | 17.8 | | 64.3 |
| **PAT** | **165.9** | **79.5** | **108.7%** | **62.4** | **165.8%** | **267.4** |
| **PAT Margin** | **9.3%** | **6.2%** | | **4.7%** | | **5.1%** |
| Other Comprehensive Income | -1.8 | 1.9 | | 71.8 | | 126.8 |
| **Total Comprehensive Income** | **164.1** | **81.4** | **101.7%** | **134.3** | **22.2%** | **394.2** |
| EPS | 46.80* | 22.42* | | 17.60* | | 75.41 |

Fatty Alcohol prices in this quarter increased to an average price of $ 2,806/MT vs Q4 when it stood at $ 2,751/MT. The same was $ 2,723/MT in Q1FY26

As per Ind AS *Not Annualised #Statutory Impact of New Labour Codes

# Standalone Profit & Loss Statement

GALAXY
Chemistry Creates Care

| Particulars (Rs. In Crores) | Q1FY27 | Q1FY26 | Y-o-Y | Q4FY26 | Q-o-Q | FY26 |
|---|---|---|---|---|---|---|
| Net Revenue from Operations | **1,265.5** | **874.1** | **44.8%** | **928.3** | **36.3%** | **3,589.1** |
| Other Income | 6.8 | 6.5 | | 6.2 | | 29.6 |
| **Total Revenue** | **1,272.3** | **880.6** | **44.5%** | **934.5** | **36.1%** | **3,618.7** |
| Cost of Material Consumed | 931.4 | 672.8 | | 712.6 | | 2,782.3 |
| Employee's Benefits Expense | 52.6 | 46.2 | | 47.3 | | 181.6 |
| Other Expenses | 114.5 | 79.4 | | 88.6 | | 337.9 |
| **EBITDA** | **173.8** | **82.2** | **111.3%** | **86.0** | **102.0%** | **316.8** |
| **EBITDA Margin** | **13.7%** | **9.3%** | | **9.2%** | | **8.8%** |
| Depreciation | 23.0 | 18.0 | | 20.7 | | 75.4 |
| **EBIT** | **150.8** | **64.2** | **134.9%** | **65.4** | **130.7%** | **241.5** |
| Finance cost | 8.7 | 5.7 | | 7.8 | | 27.6 |
| **PBT (Before Exceptional)** | **142.0** | **58.5** | **143.0%** | **57.6** | **146.8%** | **213.9** |
| Exceptional Item | 0.0 | 0.0 | | 0.0 | | 11.9# |
| **PBT (AfterExceptional)** | **142.0** | **58.5** | **143.0%** | **57.6** | **146.8%** | **202.0** |
| Tax expense | 36.1 | 16.4 | | 13.5 | | 49.9 |
| **PAT** | **105.9** | **42.0** | **152.0%** | **44.1** | **140.2%** | **152.0** |
| **PAT Margin** | **8.3%** | **4.8%** | | **4.7%** | | **4.2%** |
| Other Comprehensive Income | -0.5 | -0.1 | | 3.4 | | 3.0 |
| **Total Comprehensive Income** | **105.4** | **41.9** | **151.6%** | **47.5** | **121.7%** | **155.1** |
| EPS | 29.88* | 11.86* | | 12.44* | | 42.88 |

As per Ind AS *Not Annualised #Statutory Impact of New Labour Codes

# Managing Volatility in Raw Material Prices and Currency...

**Fatty Alcohol Prices (USD / MT)**




**INR / USD Prices**




... through Robust Risk Management Practices

Source: Market Prices – ICIS – LOR

Source: RBI

# Thank You

**Company**


GALAXY
Chemistry Creates Care

CIN No: L39877MH1986PLC039877

Mr. Ruchir Soni

Email: Ruchir.Soni@galaxysurfactants.com

www.galaxysurfactants.com


**Investor Relations Advisors :**


SGA Strategic Growth Advisors

CIN - U74140MH2010PTC204285

Mr. Mandar Chavan / Mr. Rahul Agarwal

mandar.chavan@sgapl.net /

rahul.agarwal@sgapl.net

+91 96993 82195 / +91 98214 38864

www.sgapl.net